

# Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders

NCT07037732

---

**Status** RECRUITING  
**Sponsor** Centre Hospitalier Universitaire de Nice  
**Enrollment** 50 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Patient who undergo rituximab treatment according to routine care and having one of the following disorder:
- primary immune thrombocytopenia
- primary autoimmune hemolytic anemia
- systemic lupus erythematosus
- systemic sclerosis
- ... and 4 more (see full listing online)

### Exclusion (1)

- Patients undergoing multiple immunosuppressive drugs because of refractory disease or concomitant hemopathy or malignancy

## Locations (1 total)

---

Chu de Nice, Nice, Alpes Maritimes, France